Quarterly report pursuant to Section 13 or 15(d)

Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)

v3.21.1
Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Mar. 31, 2021
Mar. 31, 2020
Net earnings, including noncontrolling interest $ 45,402 $ 46,144 $ 33,395 $ 36,432 $ 119,622 $ 14,398 $ 124,941 $ 170,451
Net earnings (loss) attributable to noncontrolling interest (380)     0     (509) 0
Net earnings attributable to Bio-Techne 45,782     36,432     125,450 170,451
Income allocated to participating securities (27)     (26)     (77) (126)
Income available to common shareholders $ 45,755     $ 36,406     $ 125,373 $ 170,325
Basic (in shares) 38,856     38,303     38,693 38,167
Basic (in dollars per share) $ 1.18     $ 0.95     $ 3.24 $ 4.46
Income allocated to participating securities $ (27)     $ (26)     $ (77) $ (126)
Income available to common shareholders $ 45,755     $ 36,406     $ 125,373 $ 170,325
Dilutive effect of stock options and restricted stock units (in shares) 1,820     1,132     1,612 1,187
Diluted (in shares) 40,676     39,435     40,305 39,354
Diluted (in dollars per share) $ 1.12     $ 0.92     $ 3.11 $ 4.33